Active Clinical Trials
Find a Clinical Trial
A multicenter, double-blind, randomized withdrawal extension study of subcutaneous secukinumab in prefilled syringes to demonstrate long-term efficacy, safety and tolerability up to 2 years in subjects with moderate to severe chronic plaque-type psoriasis completing preceding psoriasis phase III studies with secukinumab [CAIN457A2302E1]
A Phase 1/2 Multicenter, Randomized, Open-label, Dose-escalation Study To Determine The Maximum Tolerated Dose, Safety, And Efficacy Of Cc-4047 Alone Or In Combination With Dexamethasone In Patients With Relapsed And Refracotry Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide And Bortezomib
A Phase 3b, Randomized, Double-Blind, Double-Dummy Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate (DF) Monotherapy Versus Emtricitabine plus Tenofovir DF Fixed-Dose Combination Therapy in Subjects with Chronic Hepatitis B who are Resistant to Lamivudine. (GS-US-174-0121)
A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon _-2a (Pegasys) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon _-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB)
A Phase II, Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination with Telaprevir and Pegasys®/Copegus® Compared with Telaprevir and Pegasys®/Copegus® in Patients with Chronic Hepatitis C Genotype 1 Virus Infection Who Were Prior Null Responders to Treatment with Pegylated Interferon/Ribavirin (Protoocol #NV27779)
A Phase III, Multi-center, Randomized, 24 Week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-blind Treatment Period.
A Phase III, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Two fixed dose combinations of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo for 24-Weeks treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to C. Difficile Toxin A and B) in Patients Receiving Antibiotic Therapy for C. Difficile Infection (MODIFY II)
Joel J.F. Oger
VCH researchers are engaged in a wide variety of clinical trials and research studies investigating new approaches to preventing and treating conditions and diseases.
The variety of therapies studied range from new pharmaceutical drugs and medical devices to behavioral and biotechnology therapies.
These trials and studies are done in close collaboration with scientists and physicians from many areas of expertise across Vancouver Coastal Health and the University of British Columbia.
- Research Centres
- Brain Research Centre
- Centre for Clinical Epidemiology & Evaluation [C2E2]
- Centre for Hip Health & Mobility [CHHM]
- Centre for Respiratory, Cardiology, and Critical Care Medicine
- Immunity and Infection Research Centre
- International Collaboration On Repair Discoveries [ICORD]
- Vancouver Prostate Centre
- Research Programs
- Research Areas
- Research Communities
- Research Clinics
- Research Studies
- Active Clinical Trials
- Researcher Directory
- Related Research Links
- Multiple Sclerosis - CCSVI
Researchers, if you haven’t confirmed your information for the Researcher Directory, please complete the online form.